{'fraction_non_alphanumeric': 0.024727992087042534, 'fraction_numerical': 0.002967359050445104, 'mean_word_length': 5.445859872611465, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pharmacological fMRI and EEG for the development of novel analgesic compounds. André MOURAUX. Chargé de recherches

Functional magnetic resonance imaging (fMRI) and electroencephalography (EEG) have been introduced in pharmacological studies with the aim to measure the modulation of brain activity by drugs acting directly on the central nervous system (CNS) or indirectly on its afferent input. By providing novel and specific biomarkers which could substitute or complement clinical endpoints, this approach is thought to have the potential to contribute to the early clinical stages of drug development, and, in particular, to the development of novel analgesic compounds. Here, we shall (1) examine the ability of these methods to investigate the actions of drugs on the CNS, (2) review the studies of analgesic drugs which have already used these techniques, and (3) discuss potential caveats in interpreting modulations of fMRI and EEG activity as reflective of drug-induced changes in neuronal activity.